Jr Joseph Paul Woodard Net Worth

The estimated Net Worth of Jr Joseph Paul Woodard is at least $528 dollars as of 13 November 2019. Jr Woodard owns over 3,750 units of Bellicum Pharmaceuticals Inc stock worth over $528 and over the last 6 years Jr sold BLCM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jr Woodard BLCM stock SEC Form 4 insiders trading

Jr has made over 1 trades of the Bellicum Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Jr exercised 3,750 units of BLCM stock worth $280 on 13 November 2019.

The largest trade Jr's ever made was exercising 3,750 units of Bellicum Pharmaceuticals Inc stock on 13 November 2019 worth over $280. On average, Jr trades about 1,250 units every 0 days since 2019. As of 13 November 2019 Jr still owns at least 7,064 units of Bellicum Pharmaceuticals Inc stock.

You can see the complete history of Jr Woodard stock trades at the bottom of the page.

What's Jr Woodard's mailing address?

Jr's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON, TX, 77030.

Insiders trading at Bellicum Pharmaceuticals Inc

Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli..., and Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.

What does Bellicum Pharmaceuticals Inc do?

bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.

Complete history of Jr Woodard stock trades at Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals Inc executives and stock owners

Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Richard Fair,
  President, Chief Executive Officer, Director
• Richard A. Fair,
  Pres, CEO & Director
• Shane Ward,
  Corporate Secretary, Chief Legal and Strategy Officer
• Charity D. Scripture M.S., Pharm.D.,
  Chief Devel. Officer
• James Brown,
  Independent Chairman of the Board
• Jon Stonehouse,
  Independent Director
• Reid Huber,
  Independent Director
• Stephen Davis,
  Independent Director
• Judith Klimovsky,
  Independent Director
• James Daly,
  Independent Director
• David Strauss,
  Corporate Controller
• Aaron Foster,
  Senior Vice President, Head of Research
• Atabak Mokari,
  Chief Financial Officer
• Charity Scripture,
  Chief Devel. Officer
• Dr. Aaron E. Foster,
  Head of Research & Sr. VP
• Dr. Alan K. Smith Ph.D.,
  Chief Scientific Officer
• Joseph Senesac,
  Sr. VP of Technical Operations & Quality
• Charles S. Grass,
  Principal Accounting Officer
• Alan A Musso,
  CFO and Treasurer
• Thomas J. Farrell,
  President and CEO
• Frank B. Mc Guyer,
  Director
• Alan K. Smith,
  EVP, Technical Operations
• Ken Moseley,
  Vice President
• Kevin M. Slawin,
  CMO and CTO
• Bros. Advisors Lpbaker Feli...,
  
• Peter L. Hoang,
  Sr. VP of Bus. Development
• Annemarie Moseley,
  Chief Operating Office and EVP
• Rosemary Y. Williams,
  VP, Finance & PAO
• Gregory S. Naeve,
  Chief Business Officer
• Bros. Advisors Lp Baker Bro...,
  
• Edmund Harrigan,
  Director
• William Grossman,
  Sr. VP, Chief Medical Officer
• David M. Spencer,
  Chief Scientific Officer
• Jr Joseph Paul Woodard,
  SVP Clinical & Medical Affairs
• Joseph Senesac,
  VP of Manufacturing
• Investments Ltd. Mc Guyer,
  10% owner
• Ventures Llc Remeditex,
  10% owner
• Charity Scripture,
  Chief Development Officer
• Bros. Advisors Lpbaker Juli...,